Mitochondrial function as a therapeutic target in heart failure
David A. Brown(The University of Sydney), Mihai Gheorghiade(Northwestern University), Stephen J. Greene(Duke Medical Center), Burkert Pieske(Berlin Institute of Health at Charité - Universitätsmedizin Berlin), John G.F. Cleland(University of Glasgow), Gerasimos Filippatos(National and Kapodistrian University of Athens), Saame Raza Shaikh(University of North Carolina at Chapel Hill), Wilson S. Colucci(Boston University), Justin B. Perry(Virginia Tech), Adriaan A. Voors(University Medical Center Groningen), Javed Butler(Saint Luke's Health System), Brian L. Stauffer(University of Colorado Denver), Hani N. Sabbah(Henry Ford Hospital), Bertram Pitt(University of Michigan), Mitchell E. Allen(Virginia Tech), Stefan D. Anker(Bayer (Germany))
Cited by 786
Related Papers
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|European Heart Journal|2021|13.1k
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
|New England Journal of Medicine|2017|9.1k
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC
|European Heart Journal|2012|6.9k
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k